Somaxon Pharmaceuticals is a specialty pharmaceutical company established in 2003, focusing on bringing proprietary branded prescription therapeutics to market to address significant medical conditions with unmet needs or high patient dissatisfaction. The company emphasizes in-licensing, developing, and marketing unique products and late-stage candidates, primarily within the central nervous system therapeutic area.
Currently, Somaxon is actively promoting Silenor®, which is the first and only nonscheduled prescription medication approved for the treatment of sleep maintenance insomnia. Silenor is now available for prescription in the United States.
The company secured a significant $6.00M post-IPO equity investment on 08 July 2009. The investors in this round included Montreux Equity Partners, MPM Capital, Prospect Venture Partners, Domain Associates, Scale Venture Partners, and Tavistock Life Sciences.
Somaxon Pharmaceuticals operates within the Biotechnology, Health Care, and Pharmaceutical industries.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Post-IPO Equity | $6.00M | 6 |
|
08 Jul 2009 |
| Series C | $65.00M | 4 |
|
06 Jun 2005 |
| Series B | $23.00M | - | 15 Jun 2004 |
No recent news or press coverage available for Somaxon Pharmaceuticals.
We care about your data, and we'd love to use cookies make your experience better.
